Board Certified Pharmacotherapy Specialists are at the forefront of treatment of patients with atrial fibrillation (AF). Recommendations regarding rate versus rhythm control as well as the role of direct oral anticoagulants in valvular AF has evolved over the past several years. There is emerging data suggesting the early use of rhythm control in AF patients as well as the potential role of DOACs in patients with valvular AF. Part one of this program will explore the following topics: the evolution of clinical evidence for rate vs. rhythm control in the treatment of AF and patient characteristics that support early rhythm-control therapy. Part two of the program will provide an overview of the evolution of the definition of valvular AF and discuss an evidence-based anticoagulation regimen for treating patients with valvular AF. Participants will have the opportunity to attend one or both educational activities. Each activity will offer 3.0 contact hours of continuing pharmacy education credit toward BCPS recertification credit upon completion of a required posttest by the submission deadline and achievement of a predetermined passing score. The posttest will be available on November 9, 2022. The deadline to submit posttests and earn recertification credit for the session will be November 9, 2023. If you have not already purchased the posttest and wish to add it to your registration, email [email protected] or visit the registration desk on or before Oct. 18, 2022.